Research results show that PARP inhibitors have curative effects on prostate cancer, pancreatic cancer, and small cell lung cancer.[12] In a meta-analysis of platinum-sensitive recurrent ovarian cancer by Tomao et al, it was shown that PARP inhibitors are effective for patients regardless of BRCA mutation status.[13]. Here, PARP1 is linked to prostate carcinoma.